Monday, 9 Jun 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • White
  • VIDEO
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Colossal
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
Health and Wellness

Woman Dies After Using Weight-Loss Drug In U.K.’s First Case

Last updated: November 9, 2024 9:12 pm
Share
Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
SHARE

A tragic incident has occurred in the U.K. involving a 58-year-old nurse named Susan McGowan who passed away after taking two doses of the weight-loss medication tirzepatide, also known as Mounjaro or Zepbound. According to reports, McGowan’s death was attributed to multiple organ failure, septic shock, and pancreatitis, with the Eli Lilly drug listed as a contributing factor on her death certificate.

McGowan had purchased the prescription for tirzepatide online and had taken two low doses of the drug over a period of two weeks. Shortly after her second dose, she began experiencing severe stomach pain and sickness, prompting her to seek treatment at University Hospital Monklands where she had worked for three decades. Unfortunately, her condition worsened, leading to kidney issues, coma, and eventually organ failure.

Tirzepatide is categorized as a GLP-1 receptor agonist, a class of weight-loss drugs that help reduce appetite by inducing a feeling of fullness. Similar to Novo Nordisk’s Ozempic, tirzepatide is known for its effectiveness in weight loss and managing type two diabetes. However, it is also associated with side effects such as vomiting, diarrhea, and nausea, and in rare cases, severe allergic reactions, kidney problems, stomach issues, and thyroid tumors.

Despite these risks, regulatory authorities maintain that the benefits of tirzepatide outweigh the potential drawbacks. The U.K.’s Medicines and Healthcare products Regulatory Authority approved the drug as a weight loss aid in 2023, closely monitoring adverse events through the Yellow Card reporting scheme. While a second death is under investigation for possible links to tirzepatide, no conclusive evidence has been established.

In response to the incident, Dr. Alison Cave, Chief Safety Officer at MHRA, emphasized the organization’s commitment to patient safety and the rigorous assessment of medicines before approval. Eli Lilly, the manufacturer of tirzepatide, also reiterated its dedication to monitoring and reporting safety information for all its products.

See also  Antibiotic-resistant bacteria could pose major health threat across Asia

As investigations continue into the circumstances surrounding Susan McGowan’s tragic death, it serves as a poignant reminder of the importance of patient safety and thorough evaluation of medication risks and benefits. Our thoughts are with McGowan’s family during this difficult time, and we hope that lessons learned from this incident will contribute to enhanced safety measures in the healthcare industry.

TAGGED:caseDiesDrugU.K.sWeightLossWoman
Share This Article
Twitter Email Copy Link Print
Previous Article Emilia Wickstead Resort 2025 Collection Emilia Wickstead Resort 2025 Collection
Next Article Days Before The Election Trump Melts Down Because He Isn’t Running Against Biden Days Before The Election Trump Melts Down Because He Isn’t Running Against Biden
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

JJ thought it was the best idea

A recent viral video featuring YouTuber Vikram "Vikkstar123" has shed light on Olajide "JJ," popularly…

September 28, 2024

Our favorite startups from Pear VC’s invitational demo day

Pear VC Launches Expanded Accelerator Program, PearX Pear VC, a well-known pre-seed and seed-focused venture…

October 15, 2024

Even Trump’s Most Devoted Supporters Are Furious With Him Over Latest Move

Donald Trump is facing backlash from both conservatives and Democrats over his acceptance of a…

May 12, 2025

NJ teens accused of setting Jones Road Wildfire told cops Mexicans started it

The Jones Road Wildfire in New Jersey, which has burned over 15,000 acres, was initially…

May 3, 2025

Tamara Lanier on Her Historic Victory Against Harvard University 

But through oral history, through the stories that were passed down from my mother, I…

May 29, 2025

You Might Also Like

UnitedHealth’s talking points, doctors up for a pay raise
Health and Wellness

UnitedHealth’s talking points, doctors up for a pay raise

June 9, 2025
CDC layoffs, TMS therapy, MAHA players
Health and Wellness

CDC layoffs, TMS therapy, MAHA players

June 9, 2025
An investor makes a case for funding sex, drugs and other socially taboo products
Tech and Science

An investor makes a case for funding sex, drugs and other socially taboo products

June 9, 2025
The stress of improvising hospital-level child care at home
Health and Wellness

The stress of improvising hospital-level child care at home

June 9, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?